Home > Oncology > ASCO 2022 > Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma

Presented By
Prof. Eric Bouffet, University of Toronto, Canada
Conference
ASCO 2022
The non-chemotherapeutic combination of dabrafenib and trametinib outperformed standard-of-care chemotherapy in paediatric patients with BRAF V600-mutated low-grade glioma. With the manageable safety profile, it shows potential as a new standard-of-care for this population. Gliomas, accounting for approximately 45% of all paediatric central nervous system tumours, are surgically treated if possible [1]. Unfortunately, about 50% of these tumours cannot be resected, because the tumours are too large or inaccessible. Chemotherapy is the first-line standard of care in these patients. However, paediatric patients with BRAF V600E mutations show a less favourable response to chemotherapy and novel therapeutic options are needed for these patients [2]. Prof. Eric Bouffet (University of Toronto, Canada) presented results from a phase 2 trial (NCT02684058) which rand...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on